About this item:

534 Views | 363 Downloads

Author Notes:

Correspondence should be addressed to Kevin D. Bunting, kevin.bunting@emory.edu and Cheng-Kui Qu, cheng-kui.qu@case.edu

Academic Editor: Michael H. Tomasson

X. Liu and H. Sabnis contributed equally to this paper.


Research Funding:

This work was supported by the National Institutes of Health Grants HL068212 and HL095657 (to C.-K. Q.), DK059380 (to K. D. Bunting), Cure Childhood Cancer Foundation (to K. D. Bunting and H. Sabnis), Rally Foundation for Childhood Cancer Research (to K. D. Bunting), and the Case Comprehensive Cancer Center Cancer Stem Cell Pilot Grant (to C.-K. Qu).

Molecular Targets for the Treatment of Juvenile Myelomonocytic Leukemia


Journal Title:

Advances in Hematology


Volume 2012, Number 2012


, Pages 1-7

Type of Work:

Article | Final Publisher PDF


Significant advances in our understanding of the genetic defects and the pathogenesis of juvenile myelomonocytic leukemia (JMML) have been achieved in the last several years. The information gathered tremendously helps us in designing molecular targeted therapies for this otherwise fatal disease. Various approaches are being investigated to target defective pathways/molecules in this disease. However, effective therapy is still lacking. Development of specific target-based drugs for JMML remains a big challenge and represents a promising direction in this field.

Copyright information:

© 2012 Xiaoling Liu et al.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/).

Creative Commons License

Export to EndNote